A COMPARATIVE STUDY ON THE EFFECT OF FLUOROQUINOLONES IN EXPERIMENTAL SEIZURES ON WISTAR RATS: AN ACUTE STUDY
Objective: To compare the convulsive profile of three different Fluoroquinolones namely Ciprofloxacin, Levofloxacin and Ofloxacin using Maximal Electro Shock (MES) as an experimental seizure model.
Methods: Wistar rats were divided into 8 groups with 6 animals each. Group I was administered Gum acacia 1 % solution (control), Group II with Standard drug, Sodium Valproate and Group III-VII received 25 mg/kg and 50 mg/kg of Ciprofloxacin, Levofloxacin and Ofloxacin each respectively. After 45 min of administration of drugs, animals were subjected to MES.
Results: Ciprofloxacin prolonged various phases of MES, Ciprofloxacin 50 mg/kg group increased Tonic Hindlimb Extensor (THE) duration by 91% compared to the control group which was statistically significant. Levofloxacin group exhibited pro convulsive activity which was not significant. Ofloxacin 50 mg/kg group exhibited 80% reduction in the duration of tonic hind limb extensor phase and early recovery phase compared to control group (4.2Â±1.09 s and 169.33Â±5.3 s) respectively, proven statistically significant. Ofloxacin group exhibited anticonvulsant like activity.
Conclusion: Fluoroquinolones are the popular class of antimicrobials used in a variety of infections. However, conflicting experimental evidence regarding central neurotoxicity especially seizures, complicate their use and required further investigation. Our results suggest that older generation Fluoroquinolones like Ciprofloxacin exhibits significant dose-dependent pro convulsive activity. Hence, their use must be judiciously restricted in patients with predisposing epileptogenic factors. Levofloxacin had no significant pro convulsant activity. Ofloxacin on higher dose appears to be protective exhibiting an anticonvulsant like activity. Hence, if need be, newer generation Fluoroquinolones should be preferred.
2. Pesola GR, Avarsarala J. Bupropion seizure proportion among new-onset generalized seizures & drug related seizures presenting to an emergency department. J Emerg Med 2002;22(3):235â€“9.
3. Kushner JM, Peckman HJ, Snyder CR. Seizures associated with fluoroquinolones. Ann Pharmacother 2001;35(10):1194-8.
4. LL Chabner BA, Knollmann BC. Sulfonamides, Trimethoprim-Sulfamethoxazole, Quinolones, and agents for urinary tract Infections. In: Goodman & Gilman's the pharmacological basis of therapeutics. 12th Ed. The McGraw-Hill Companies Inc; 2011. p. 1470-6.
5. Owens Jr, Ambrose. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005;41(2):144-57.
6. Ball P. Adverse reactions and interactions of fluoroquinolones. Clin Invest Med 1989;12:28-34.
7. Leone R, Venegoni M, Motola D, Moretti U, Piazzetta V, Cocci A. Adverse drug reactions related to the use of ï¬‚uoroquinolone antimicrobials: an analysis of spontaneous reports and ï¬‚uoroquinolone consumption data from three Italian regions. Drug Saf 2003;26:109â€“20.
8. Wolfson JS. Overview of fluoroquinolone safety. Am J Med 1991;91(Suppl 6A):153-61.
9. Gupta SK. Drug screening methods, Jaypee Brothers Medical Publishers New Delhi; 2009.
10. Castel-Branco MM, Alves GL, Figueiredo IV, FalcÃ£o AC, Caramona MM. The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs. Methods Find Exp Clin Pharmacol 2009;31(2):101-6.
11. Matrindale-The Complete Drug Reference. 36th Edition. Pharmaceutical Press: London; 2009.
12. Akahane K, Sekiguchi M, Une T, Osada Y. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites. Antimicrob Agents Chemother 1989;33:1704â€“8.
13. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994;33;685â€“706.
14. Rewari S, Prabhu S. A comparative experimental study of proconvulsive potential of Fluoroquinolones. Indian J Pharmacol 1999:31(1);29-32.
15. Louis D Saravolatz, James Leggett. Gatifloxacin, Gemifloxacin, and Moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis 2003:37(1);1210-5.
16. Hori S, Shimada J, Saito A. Comparison of the inhibitory effects of new quinolones on gamma-aminobutyric-acid receptor binding in the presence of anti-inflammatory drugs. Rev Infect Dis 1989;(Suppl 5):1397-8.
17. Davey PG, Charter M, Kelly S, Varma TRK, Jacobson I. Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABA-A receptor of rat vagus nerve. Antimicrob Agents Chemother 1994:38;1356-62.
18. Walton GD, Hon JK, Mulpur TG. Ofloxacin induced seizures. Ann Pharmacother 1997:3;1475-7.
19. De Sarro A, De Sarro G. Adverse reactions to fluoroquinolones. An overview on mechanistic aspects. Curr Med Chem 2001:8(4);371â€“84.
20. Egerbacher M, Seiberl G, Wolfesberger G, Walter I. Ciprofloxacin causes cytoskeletal changes and detachment of human and rat chondrocytes in vitro. Arch Toxicol 2000:73;557-63.
21. Stahlmann RJ, Vormann T, Gunther C, Forster U, Zippel E, Lozo R. Effects of quinolones, magnesium deficiency or zinc deficiency of joint cartilage in rats. Magnesium Bull 1997:19;7-22.